Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Araxes Pharma Enters into Agreement with Janssen Biotech

Published: Friday, March 01, 2013
Last Updated: Friday, March 01, 2013
Bookmark and Share
Cancer drug discovery and development agreement to develop first-in-class therapeutics for the treatment of cancer.

Araxes Pharma LLC has announced that it has entered into an exclusive arrangement with Janssen Biotech, Inc. to develop first-in-class therapeutics against a certain target for the treatment of cancer.

Araxes Pharma brings together a proven team of early drug developers. The scientific founders are Kevan Shokat, Ph.D., HHMI Investigator and Professor of Molecular and Cellular Pharmacology at UCSF, and Frank McCormick, Ph.D., FRS, Professor and Director of the Helen Diller Family Comprehensive Cancer Center at UCSF.

Joining them in the new venture are Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, Yi Liu, Ph.D., Chief Scientific Officer, and Pingda Ren, Ph.D., Senior Vice President of Chemistry.

Drs. Wilson, Liu, Ren and Shokat previously co-founded Intellikine, which discovered three drug candidates against the PI3K/mTOR pathway. The first drug candidate, a PI3Kdelta/gamma inhibitor, was licensed to Infinity Pharmaceuticals in July 2010 in a deal valued up to $489 million.

Separately, Intellikine advanced two more drug candidates-a TORC1/2 inhibitor and a PI3Kalpha inhibitor-into human clinical trials.

In January 2012, Millennium Pharmaceuticals, the Takeda Oncology Company, acquired Intellikine in a deal valued up to $310 million.

The Intellikine co-founders recently reunited to form Wellspring Biosciences, a pharmaceutical incubator focused on the discovery and development of drugs targeting signal transduction networks for the treatment of cancer and other serious diseases.

Wellspring is organized as a drug discovery incubator, with its scientific programs organized in separate, asset-centered affiliates. Araxes Pharma LLC represents the first publicly announced affiliate.

Under the agreement with Janssen Biotech, Araxes Pharma will advance its program through Phase I to clinical proof-of-concept. Thereafter, Janssen Biotech will have sole responsibility for the continued development and worldwide commercialization of products arising under the agreement.

Araxes Pharma will receive an upfront payment and research and development funding and is eligible to receive milestone payments in addition to tiered royalties on the worldwide sales of products under the agreement.

"We are delighted to work with Janssen on a very exciting approach for the treatment of patients with cancer," said Troy Wilson, President and CEO of Araxes Pharma.

Wilson continued, "Their sophisticated outlook and capabilities for development of molecularly-targeted therapeutics will enable us to accelerate development of our novel, high-quality small molecules."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
How to Control Shape, Structure of DNA and RNA
Researchers have used computational modelling to shed light on precisely how charged gold nanoparticles influence the structure of DNA and RNA.
Advancing Genome Editing of Blood Stem Cells
Genome editing techniques for blood stem cells just got better, thanks to a team of researchers at USC and Sangamo BioSciences.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos